Consolidated Statements of Cash Flows (USD $)	9 Months Ended		128 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Cash flows from operating activities
Net loss	$ (12,897,844)	$ (6,896,479)	$ (122,509,464)
Adjustments to reconcile net loss to net cash used in operating activities
Stock payable for acquired research and development			112,440
Stock issued for acquired research and development			26,286,589
Stock issued for services			2,061,743
Stock issued for debt in excess of principal			109,070
Amortization of discount on notes payable due to warrants and beneficial conversion feature	1,613,354	34,600	8,470,084
Loss on extinguishment of debt	2,518,912		906,472
Depreciation	258,144	225,365	1,908,302
Amortization of debt financing costs	125,248	24,710	708,265
Option and warrant expense	924,961	542,766	17,190,894
(Gain) loss on derivative instruments		136,889	(1,941,826)
Loss on disposition of fixed assets			513,345
Changes in:
Other current assets	20,481	(1,025,807)	(1,132,572)
Accounts payable - third parties and related parties	216,938	(130,278)	56,287
Accrued expenses	745,999	(219,372)	1,351,237
Deferred revenue	4,082,226		4,082,226
Other assets	(85,047)		(85,047)
Net cash used in operating activities	(2,476,628)	(7,307,606)	(61,911,955)
Cash flows from investing activities
Purchase of property & equipment	(214,197)	(512,048)	(2,436,396)
Restricted cash	1,000,000	(1,000,000)
Net cash provided by (used in) investing activities	785,803	(1,512,048)	(2,436,396)
Cash flows from financing activities
Common stock and warrants sold for cash, net of offering costs	21,319,153		70,772,950
Common stock repurchased and canceled			(325)
Proceeds from exercise of warrants and options			1,248,588
Deferred financing and offering costs	(147,847)	(136,943)	(657,339)
Repayments on notes payable	(450,000)		(761,222)
Net cash provided by financing activities	21,271,306	3,948,057	84,520,836
Net change in cash and cash equivalents	19,580,481	(4,871,597)	20,172,485
Cash and cash equivalents at beginning of period	592,004	7,109,215
Cash and cash equivalents at end of period	20,172,485	2,237,618	20,172,485
Cash paid for:
Income tax
Interest	19,638	1,460	174,747
NON-CASH TRANSACTIONS
Issuance of common stock to Sportan shareholders			147,733
Issuance of common stock for accrued interest	188,543		977,830
Issuance of warrants to placement agent			37,453
Conversion of notes payable and accrued interest to common stock	4,275,053		11,985,033
Conversion of accrued liabilities to common stock			197,176
Conversion of accounts payable to note payable			93,364
Discount on convertible notes relating to:
Warrants	195,969	2,314,635	6,170,341
Beneficial conversion feature	141,829	1,497,634	3,444,982
Stock attached to notes			1,287,440
Fair value of derivative instrument			4,680,220
Derivative reclassified to equity			2,349,266
Unpaid additions to property and equipment	5,417	11,730	5,417
Amortization of deferred offering costs to paid-in capital			47,339
Shares issued as deferred offering costs	1,234		150,365
Unpaid offering costs	296,884	170,831	296,884
Third Parties
Cash flows from financing activities
Proceeds from convertible debt	550,000	3,455,000	13,288,184
Related Parties
Cash flows from financing activities
Proceeds from convertible debt	100,000	630,000	730,000
Repayments on notes payable	$ (100,000)		$ (100,000)